Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6613830 | 0.78 | MEN1 (1.00) | MEN1KMT2A | |
| SCHEMBL1533408 | 0.78 | MEN1 (1.00) | MEN1KMT2A | |
| SCHEMBL2351676 | 0.78 | MEN1 (1.00) | MEN1KMT2A | |
| SCHEMBL31255773 | 0.78 | MEN1 (1.00) | MEN1KMT2A | |
| SCHEMBL2351672 | 0.78 | MEN1 (1.00) | MEN1KMT2A | |
| SCHEMBL2351669 | 0.78 | MEN1 (1.00) | MEN1KMT2A | |
| SCHEMBL296319 | 0.75 | TSHR (0.36) | — | |
| SCHEMBL891743 | 0.75 | TSHR (0.36) | — | |
| SCHEMBL14484474 | 0.75 | TSHR (0.36) | — | |
| Rel-Menthone SCHEMBL3965684 | 0.67 | EP300 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214834-B2 | Process for preparing enantiomerically pure 1,1′-spirobiindane-6,6′-diol derivatives | EASTMAN KODAK COMPANY (US) | 2007-05-08 | — | — | US | claimed |
| EP-1768943-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE 1,1'-SPIROBIINDANE-6,6'-DIOL DERIVATIVES | EASTMAN KODAK COMPANY (US) | 2007-04-04 | — | — | EP | claimed |
| WO-2006019663-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE 1,1'-SPIROBIINDANE-6,6'-DIOL DERIVATIVES | EASTMAN KODAK COMPANY (US) | 2006-02-23 | — | — | WO | claimed |
| US-20060020150-A1 | Process for preparing enantiomerically pure 1,1'-spirobiindane-6,6'-diol derivatives | EASTMAN KODAK COMPANY | 2006-01-26 | — | — | US | claimed |
| US-7214834-B2 | Process for preparing enantiomerically pure 1,1′-spirobiindane-6,6′-diol derivatives | EASTMAN KODAK COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1768943-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE 1,1'-SPIROBIINDANE-6,6'-DIOL DERIVATIVES | EASTMAN KODAK COMPANY (US) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006019663-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE 1,1'-SPIROBIINDANE-6,6'-DIOL DERIVATIVES | EASTMAN KODAK COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060020150-A1 | Process for preparing enantiomerically pure 1,1'-spirobiindane-6,6'-diol derivatives | EASTMAN KODAK COMPANY | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020150-A1 | Process for preparing enantiomerically pure 1,1'-spirobiindane-6,6'-diol derivatives | HSD11B1, PKD1, REN | MEN1 1196/4885KMT2A 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.